key: cord-0903462-0i5ozjlt
authors: He, Zhesheng; Ye, Fei; Zhang, Chunyu; Fan, Jiadong; Du, Zhongying; Zhao, Wencong; Yuan, Qing; Niu, Wenchao; Gao, Fuping; He, Bo; Cao, Peng; Zhao, Lina; Gao, Xuejiao; Gao, Xingfa; Sun, Bo; Dong, Yuhui; Zhao, Jincun; Qi, Jianxun; Jiang, Huaidong; Gong, Yong; Tan, Wenjie; Gao, Xueyun
title: A comparison of Remdesivir versus Au22Glutathione18 in COVID-19 golden hamsters: a better therapeutic outcome of gold compound
date: 2021-09-03
journal: bioRxiv
DOI: 10.1101/2020.10.16.342097
sha: f620959e7028e4b20e9cff965b7749926e2876bb
doc_id: 903462
cord_uid: 0i5ozjlt

We firstly disclose single compound yields better therapeutic outcome than Remdesivir in COVID-19 hamster treatments as it is armed with direct inhibition viral replication and intrinsic suppression inflammatory cytokines expression. Crystal data reveals that Au (I), released from Au22Glutathione18 (GA), covalently binds thiolate of Cys145 of SARS-CoV-2 Mpro. GA directly decreases SARS-CoV-2 viral replication (EC50: ~0.24 μM) and intrinsically down-regulates NFκB pathway therefore significantly inhibiting expression of inflammatory cytokines in cells. The lung viral load and inflammatory cytokines in GA-treated COVID-19 transgenic mice are found to be significantly lower than that of control mice. When COVID-19 golden hamsters are treated by GA, the lung inflammatory cytokines levels are significantly lower than that of Remdesivir while their lung viral load are decreased to same level. The pathological results show that GA treatment significantly reduce lung inflammatory injuries when compared to that of Remdesivir-treated COVID-19 golden hamsters. One Sentence Summary We found that gold cluster molecule directly inhibits SARS-CoV-2 replication and intrinsically suppresses inflammatory cytokines expression in COVID-19 transgenic mouse and golden hamster model, gold cluster providing a better lung injury protection than Remdesivir in COVID-19 golden hamsters via intranasally dropping administration.

One Sentence Summary: We found that gold cluster molecule directly inhibits SARS-CoV-2 replication and intrinsically suppresses inflammatory cytokines expression in COVID-19 transgenic mouse and golden hamster model, gold cluster providing a better lung injury protection than Remdesivir in COVID-19 golden hamsters via intranasally dropping administration.

To date, over 4 Million people have succumbed to COVID-19 infections worldwide, with little sign of this global pandemic being swiftly brought under control. Despite tremendous global efforts in identifying a suitable drug against COVID-19, no drug has been proven to effectively treat COVID-19 infections. In comparison of biological agents, chemical drugs are of unique advantages in dealing with the COVID-19 pandemic: they are easily produced in large scale with low cost, thus satisfying the huge number of COVID-19 patients in low income countries.

Importantly, chemicals allow for efficient handling, storing and distributing to patients living in environments unsuitable for biological agents. Several traditional chemicals are currently repurposed for COVID-19 treatment (1, 2, 3, 4, 5, 6, 7) . For example, Remdesivir was shown to directly inhibit SARS-CoV-2 replication but failed to intrinsically suppress inflammatory cytokines expression in patients (3, 7) . In comparison, Ruxolitinib or Acalabrutinib intrinsically suppressed inflammatory cytokines expression, but failed to directly inhibit virus replication (4, 6) .

We firstly propose that single compound combination of directly inhibition viral replication and intrinsically suppression inflammatory cytokines expression should yield better therapeutic results in COVID-19 treatment. The SARS-CoV-2 M pro has been used as critical drug target for COVID-19 treatment as it plays a key role in SARS-CoV-2 replication, and organic compounds have developed to yield a Michael adduct with Cys145 of the catalytic dyad of M pro (8, 9) . We speculated that Au (I) ion would yield a Michael adduct with Cys145 of M pro as previous reports showed that the Au (I) ion, released from gold compound, inactivates Echinococcus Granulosus Thioredoxin Glutathione Reductase via covalently bind with Cys519 and Cys573 (10, 11) . While gold compound, like Auranofin (AF), have previously been approved for Rheumatoid arthritis (RA) treatment as it well suppresses inflammatory cytokines of patients (12, 13) , no such treatment is currently available for COVID-19 treatment in vivo. Here, we propose a novel compound, Au22Glutathione18, for COVID-19 treatment via directly inhibition of SARS-CoV-2 replication and intrinsically suppression of inflammation cytokines expression. We set out to investigate if this gold cluster possesses therapeutic properties in mitigating the effects of COVID-19 infections.

The gold cluster was synthesized by a chemical method (SI 1). According mass spectra studies and density functional theory (DFT) simulations, the Au22Glutathione18 (GA) molecule formula is proposed in Figure S1 . We firstly study if gold compound (AF or GA) associates with hydrophobic domain surround the catalytic dyad of M pro via molecular dynamic (MD) simulations (SI 2). In this theory study, the crystal structure of M pro was obtained from the PDB database (PDB 6LU7). The AF and GA molecular structure were performed by using GaussView 5.0 and Gaussian 09 software packages. As shown in Figure 1A , there is one hydrophobic cavity with its volume over 500 Å 3 in each M pro monomer, which surrounds the catalytic site of Cys145 (green or purple region of M pro monomer). In this work, we utilized AF or GA as ligand to complex with M pro . For the AF-M pro or GA-M pro complexing system, we studied the root-meansquare deviation (RMSD) to learn the binding stability. Obviously, the AF-M pro or GA-M pro reached binding equilibrium at about 10 ns, and the binding conformation remained stable afterwards ( Figure S2) . The average binding energy of AF-M pro and GA-M pro was ~50.47 kcal/mol. and ~722.94 kcal/mol., respectively ( Figure S3 ). The GA (yellow) and AF (orange) bind to the hydrophobic cavity around the Cys145, and this makes Au atom very close to S of Cys145 ( Figure 1B) . In AF-M pro system, Van del Vaals force plays main role to keep system stable where the Glu166 and Gln189 of M pro interact with AF via hydrogen bonds. While the electrostatic force contributes the main interaction in GA-M pro system in Figure 1B , Arg4, Arg40, Lys137 and Arg188 of M pro formed four salt bridges with glutathione of GA (with yellow S atoms).

The experimental association affinity between gold compound (AF or GA) and M pro was further studied by surface plasma resonance (SPR) method (SI 3). After M pro was fixed in chip, serial dose of gold compound (AF or GA) was introduced into solution and the time dependent optical signal were tracked. As shown in Figure 1C Figure S4 , and Table S1. In Figure 2A , the M pro molecular structures treated with AF or GA are highly similar, and share most features of the crystal structures of the apo SARS-CoV-2 M pro determined recently (8, 9) . However, crystal structural analysis showed that the densities of two Au (I) ions were found clearly to be very close to the thiol residues of Cys145 and Cys156 ( Figure 2B ). The position of two Au (I) ions was confirmed by applying the anomalous difference Fourier maps, two Au (I) ions are defined as Au(I) 1 and Au (I) 2, respectively. In Figure 2C and Figure S5 , the Au-S bond length is 2.3Å in M pro , such short bond length confirms that AF or GA can release Au (I) ions which covalently bind to the thiolate of Cys145 and Cys156 of M pro . The thiolate of Cys519 and Cys573 residues of Echinococcus Granulosus enzyme covalently interacts with Au (I) ions were previously reported (10), which supports Au (I) irreversibly interact with thiolate of Cys145 of the catalytic dyad of M pro in this study. Further temperature factor analysis shows that the occupancy of Au (I) ion is partial and the occupancy factors is about 33% for Cys145 and 11% for Cys156, indicating that the Au (I) ions released from AF or GA are gradually bind the thiolate of Cys145 and Cys156 of M pro molecules in solution.

Although the M pro monomer contains 12 Cys residues (Cys16, Cys22, Cys38, Cys44, Cys85, Cys117, Cys128, Cys145, Cys156, Cys160, Cys265, Cys300), only Cys145 and Cys156 specifically bind to the Au (I). To further verify the covalently binding of Au (I) to the S atom of Cys145 and Cys156, we calculated the interaction energies between Au and M pro protein using density functional theory (SI 6) method. Our analysis showed that the bond dissociation energies (EBD's) between Au (I) and Cys145 are ~ 46.1 kcal/mol. and that of Au (I) and Cys156 are ~ 26.5 kcal/mol. In (Figure 2D . The larger EBD value strongly suggests that the Au ion covalently bind to Cys145 and lock the active pocket of M pro , thus efficiently inhibiting catalytic activity.

To exam whether AF or GA effectively inhibits M pro activity, we determined the IC50 of AF or GA using a previously reported method (14) . M pro activity was measured using a fluorescence resonance energy transfer (FRET) assay. To this end, a fluorescence labeled substrate, (EDNAS-Glu)-Ser-Ala-Thr-Leu-Gln-Ser-Gly-Leu-Ala-(Lys-DABCYL)-Ser, derived from the autocleavage sequence of the viral protease was chemically modified for enzyme activity assay (SI 7). Figure 3A , the IC50 of AF was ~0.46 µM , and the IC50 of GA was ~0.11 µM.

To assess whether GA inhibits M pro activity in mammalian cells, we transiently transfected HEK293F cells with a plasmid of strep-tagged SARS-CoV-2 M pro gene. The M pro gene was expressed 24 hours in HEK293F cells, then GA was added to the culture medium at a final concentration of 500 µM , and cell cultured for an additional 24 hrs. After cell harvest, SARS-CoV-2 M pro extracted from GA-treated HEK293F cells was purified and analyzed for enzyme activity (SI 7). As shown in Figure S6 , the GA treated-SARS-CoV-2 M pro activity was reduced to approx. 60% of control SARS-CoV-2 M pro . ICP-MASS results indicated that when M pro was expressed in GA-treated mammalian cells, gold can bound to SARS-CoV-2 M pro ( Figure S6 ).

We failed to obtain similar results for AF in cell assays as AF exhibited strong cytotoxicity when HEK293F cell cultured with AF.

We measured the EC50 of AF or GA to evaluate if they inhibit SARS-CoV-2 replication in Vero cells, using a recently described method (5) (SI 7). As shown in Figure 3B , the EC50 of AF was approx. 0.83 µM and EC50 of GA approx. 0.24 µM. However, for Vero cell the CC50 value of AF is ~ 2.27 µM and that of GA approx. 1.11mM ( Figure S7 ). The therapeutic index (CC50/EC50) of AF is 2.73 and that of GA is 4,625, this implied GA has better potential in COVID-19 treatment.

in activation of inflammatory cytokine gene expression via the NFκB pathway, and these cytokines will in turn activate macrophages, which as a result acquire an inflammatory status to profoundly produce inflammatory cytokines (15, 16) . Recent reports revealed that among versatile inflammatory cytokines, the IL-6, IL-1β, TNF-α play key roles in inflammation development of modest and severe infections (16, 17) . We firstly assessed whether GA or AF inactivate the NFκB pathway and suppress inflammatory cytokine expression levels in inflammatory human 16HBE bronchial epithelial cells (SI 7). To test whether AF or GA inactivate the NFκB pathway in macrophage cells, and as a result down-regulate expression of IL-6, IL-1β, TNF-α, RAW264.7 macrophage was incubated with AF or GA at different concentrations for 24 hours. As shown in Figure 3C , the low dose of AF (0.6 µM) or GA (0. (Figure S7 ). This implied that GA has better safety in COVID-19 treatment.

To evaluate the safety of administering AF or GA into COVID-19 animal model, we first tested the toxicity of AF and GA. The reported mice intraperitoneal LD50 for AF was approx. 33.8 mg/kg.bw (19) , and that for GA more than 2000 mg/kg.bw (all mice survived, see SI 8). The SD rat intraperitoneal LD50 for AF was found to be approx. 25.5 mg/kg.bw (19) , while that for GA approx. 576 mg/kg.bw (SI 8). Together, these animal toxicity and aforementioned cell toxicity data ( Figure S8 ) strongly suggested that GA is safer for mice/rats treatment than AF. We therefore continued investigation of GA in a COVID-19 transgenic mouse. To evaluate whether GA inhibit SARS-CoV-2 replication and suppress lung inflammation injury, the Ad5-hACE2transduced mice were generated according to recently published methods (20) . Briefly, eighteen BALB/c mice were randomly divided into three groups, namely GA (GA treated COVID-19 mice), NS (0.9% NaCl treated COVID-19 mice), Mock (0.9% NaCl treated mock infected-mice), all mice were anesthetized with pentasorbital sodium and transduced intranasally with 2. (Figure 4B) . We found that the average number of viral RNA copies in lung of GA-treated mice was ~10 4 , significantly lower than the average number found in NS-treated infected mice ~ 10 5 (Figure 4C) . The histopathological changes in mice lung tissues were assessed by grading the injuries in accordance with the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) scoring standard. As shown in Figure 4D , the GA-treated mice significantly reduced histopathological scores (~1.8) compared with that of NStreated mice (~3.0). We further evaluated the therapeutic effects of GA using histopathological analysis of mouse lung tissues. As shown in Figure 4E , mice infected with SARS-CoV-2 showed severe lung inflammation following treatment with NS, the alveolar septum, bronchus, bronchioles and perivascular interstitium were significantly widened, along with an infiltration of higher numbers of lymphocytes and a small number of neutrophils. In addition, a small number of lymphocytes and exfoliated epithelial cells localized in the lumen of local bronchioles following NS treatment. Treatment with GA significantly abrogated lung inflammation in SARS-CoV-2 infected mice, the local alveolar septum, bronchi, bronchiole and perivascular interstitial widening significantly decreased. Although we still observed mild lymphocytic infiltration, the mucosal epithelium of bronchus and bronchioles was intact, and we failed to observe foreign bodies in the lumen in lung of GA treated mice.

Next, we measured SARS-CoV-2 spike and the key inflammatory cytokines in lung of the mice using immuno-fluorescent imaging. As shown in Figure 4F , the SARS-CoV-2 spike, IL-6, IL-1β, TNF-α expression level in the lung tissues of GA-treated infected mice were significantly lower than those found for NS-treated infected mice. Together, these results clearly demonstrated that GA inhibits virus replication, while also suppressing inflammatory cytokine expression, thus protecting the lungs of infected mice from inflammation injury.

Remdesivir was approved to treat COVID-19 in clinical now. In this study, GA is used to compare with Remdesivir to see which one is with better outcome in COVID-19 hamster treatment. A golden Syrian hamster model was generated according to recently published paper (21) . Briefly, golden hamsters were randomly divided into five groups, and Hamsters were then infected intranasally using SARS-CoV-2 (1×10 5 PFU) in a total volume of 50 μL DMEM (SI 10).

One hour after SARS-CoV-2 infection, hamsters in NS group received normal saline (0.9% NaCl), hamsters in Remdesivir group received a dose of 25mg/kg.bw, and hamsters in first GA group received a dose of 10mg/kg.bw and in second GA group received a dose of 20mg/kg.bw.

Mock group are mock-infected rats. All hamsters are treated by intranasally dropping administration. After virus infection at day 0, hamsters received GA or Remdesivir or NS treatment for further 3 times as shown in Figure 5A . All hamsters were euthanized at day 4 post infection, and several parameters were measured, including body weight loss, SARS-CoV-2 RNA copies in the lungs, pathological change in lung tissues, level of SARS-CoV-2 spikes in lung, and levels of key inflammatory cytokines (IL-6, IL-1β, TNF-α) in lungs.

GA or Remdesivir treated COVID-19 hamsters are with no significant body weight loss when compared to Mock hamsters, although NS-treated COVID-19 hamster obviously lost body weight ( Figure 5B) . We found that the average number of viral RNA copies in lung of GA (~10 3.8 in 10mg/kg.bw group and ~10 4.2 in 20mg/kg.bw group) or Remdesivir (~10 4.1 ) treated hamsters was significantly lower than that found in NS-treated infected hamsters (~10 5.5 ), GA and Remdesevir were in similar level in inhibiting virus replication in lungs of hamsters ( Figure   5C ).The histopathological changes in lung tissues are key index to assess the therapy effects of GA or Remdesivir in COVID-19 golden hamster. The lungs of hamsters were assessed by grading the injuries in accordance with the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) scoring standard. As shown in Figure 5D and 5E, the average histopathological score of virus-infected hamsters in NS group was approx. 3, the alveolar septum, bronchus, and perivascular interstitium were significantly widened, along with an infiltration of lymphocytes and neutrophils. For hamsters infected by SARS-CoV-2, treatment of Remdesivir in dose of 25mg/kg.bw got histopathological scores approx. 2.7, briefly the alveolar septum, bronchus, and perivascular interstitium were obviously widened, along with an infiltration of some of lymphocytes and neutrophils. Treatment of GA in dose of 10mg/kg.bw got pathological scores, approx. 2.3, and treatment with GA in dose of 20mg/kg.bw pathological score was approx. 2.0. GA treatment significantly decreased lung injury in comparison of Remdesivir treated SARS-CoV-2 infected hamsters. The local alveolar septum, bronchi, and perivascular interstitial widening were significantly decreased, along with an infiltration of smaller numbers of lymphocytes and neutrophils. According histopathological results, GA in dose of 10 mg/kg.bw or 20mg/kg.bw is with better therapy outcome than Remdesivir in dose of 25mg/kg.bw. Next, we measured the level of SARS-CoV-2 spikes and inflammatory cytokines in lung of the hamsters using immuno-fluorescent imaging. As shown in Figure 5F , the SARS-CoV-2 spike expression level in GA and Remdesivir treated COVID-19 hamster was significantly lower than those found in NS group, and the spike level in lung of Remdesivir group is significantly higher than that of GA group. For inflammatory cytokine level in lung of virus infected hamsters, IL-6, IL-1β, TNF-α of Remdesivir or GA-treated rat were significantly lower than those found for NStreated hamsters, and the IL-6, IL-1β, TNF-α in lung of Remdesivir group is significantly higher than that of GA group. As SARS-CoV-2 RNA copies in the lungs of GA or Remdesivir treated COVID-19 hamsters are in the same level, these immune-imaging results clearly demonstrated that GA intrinsically suppresses inflammatory cytokine expression in lungs of COVID-19 hamsters, the GA is with better outcome in suppression inflammatory cytokines expression when compared with Remdesivir.

The tissue distribution of Au and histopathological studies of GA treated mice and golden hamsters BALB/c mice (30mg GA/kg.bw via intraperitoneal injection) and golden hamster (20mg GA/kg.bw via intranasally dropping administration) were treated as description (SI 11). GA treatment resulted in none measurable side effects. Neither movement, out-looking, sleeping, nor eating behavior appeared to be affected. When we stained tissue sections with Hematoxylineosin (HE), we could not detect any pathological changes in GA-treated mice or GA-treated hamsters in Figure S8 , indicating that our treatment dose of GA was safe. Next, we analyzed Au element distribution in lung, brain, liver, spleen, heart, and kidney using an ICP-MASS approach. Table S2 and S3. The distribution of gold in lungs, hearts, livers, kidneys, brains, and spleens can be beneficial for COVID-19 treatment, as it potentially inhibits SARS-CoV-2 replication and direct suppressing the expression of inflammatory cytokines therein (15, 16, 17) .

The Au element concentration in the lung of mice (intraperitoneal injection) and hamster (intranasally dropping) was approx. ~ 78.14 µg/g and ~ 416.12 µg /g, respectively. This result showed that GA is well adsorbed by lung after intranasally dropping method, which is a good way to deliver GA into lung for inhibit virus replication and directly suppress inflammation injury therein.

In summary, our findings show that GA represents a promising therapeutic compound that combines intrinsically suppression of inflammatory cytokines expression with directly inhibition of SARS-CoV-2 replication in COVID-19 transgenic mice and golden hamsters. Via intranasally dropping, GA (10mg/kg.bw or 20mg/kg.bw) and Remdesivir (25mg/kg.bw) has similar inhibition ratio in lung viral load for COVID-19 hamsters. According histopathological studies, GA significantly suppress the lung injury when compared with Remdesivir in COVID-19

hamsters. According immuno-fluorescent observations, GA significantly suppress the lung inflammatory cytokines expression, this is attributed to GA directly inactivate NFkB pathway and further reduce inflammatory cytokines expression level in lung. The key factor that need to be considered when designing a drug for COVID-19 treatment is its toxicity. Our study showed that GA is characterized by very mild cytotoxicity and very low mice/rat acute toxicity. These features render GA an ideal candidate for safe and effective COVID-19 treatment. (E) Low dose of AF (0.6 µM) and GA (0.6µM) significantly inhibit IL-6, IL-1β, TNF-α inflammatory cytokines expression in RAW macrophages (unpaired t-test, ***p<0.001, **p <0.01, *p <0.05). (F) Low dose of AF (0.08µM) and GA (0.3µM) significantly suppress NFκB activation, thus inhibiting IL-6, IL-1β, TNF-α inflammatory cytokine expression in human 16HBE bronchial epithelial cells (unpaired t-test, ***p<0.001, **p <0.01, *p <0.05). 

Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy

Gm-csf blockade with mavrilimumab in severe covid-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Remdesivir for the treatment of Covid-19 -preliminary report

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

The Enzymatic and Structural Basis for Inhibition of Echinococcus granulosus Thioredoxin Glutathione Reductase by Gold (I)

Transduction of redox signaling by electrophile-protein reactions

New oral gold compound for treatment of rheumatoid arthritis

Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

The trinity of COVID-19: immunity, inflammation and intervention

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Cysteine-179 of IκB kinase β plays a critical role in enzyme activation by promoting phosphorylation of activation loop serines, Experimental and molecular medicine

Safety data sheet of Auranofin

Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

We thank Dr. Feng Wang (Wuxi Biortus Bioscience Co. Ltd, 6 Dongsheng West Road, Jiangyin 214437, China) provide the gift plasmid for expression SARS-CoV-2 M pro . We thank Dr. Yuanyuan Chen from Institute of Biophysics, Chinese Academy of Sciences for her technical support with the SPR assay. We thank the staffs from beamlines BL17U1, BL18U1 and BL19U1 at the Shanghai Synchrotron Radiation Facility for X-ray data collection. This work was supported by grants from National Natural Science 

The atomic coordinates of the SARS-CoV-2 M pro crystal structures in the AF incubating form, the GA incubating form, and the native form has been deposited in the Protein Data Bank under accession code 7DAT, 7DAU, and 7DAV, respectively.

Figures S1-S8Tables S1-S3References (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13)